A Phase III Randomized, Double-Blind, Placebo-Controlled Study Evaluating Dextromethorphan Plus Slow-Release Morphine for Chronic Cancer Pain Relief in Terminally Ill Patients

Journal of Pain and Symptom Management

Volumn 33, Issue 4, 2007, Pages 365-371

  Dudgeon, Deborah J ^a   Bruera, Eduardo ^a   Gagnon, Bruno ^a   Watanabe, Sharon M ^a   Allan, Sharon J ^a   Warr, David G ^a   MacDonald, Susan M ^a   Savage, Colleen ^a   Tu, Dongsheng ^a   Pater, Joseph L ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Dextromethorphan; NMDA antagonists; opioid tolerance

Indexed keywords

DEXTROMETHORPHAN; MORPHINE; PLACEBO; STATEX SR; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ANALGESIA; ARTICLE; CANCER PAIN; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SLOW DRUG RELEASE; STATISTICAL SIGNIFICANCE; TERMINALLY ILL PATIENT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; DEXTROMETHORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN, INTRACTABLE; TERMINAL CARE;

EID: 33947728305     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2006.09.017     Document Type: Article

References (19)

1. Hearn J., and Higginson I.J. Cancer pain epidemiology: a systematic review. In: Bruera E.D., and Portenoy R.K. (Eds). Cancer pain: Assessment and management (2003), Cambridge University Press, Cambridge 19-37
2. Cherny N., Frager G., and Ingham J. Opioid pharmacotherapy in the management of cancer pain. Cancer 76 7 (1995) 1283-1293
3. Mao J., Price D.D., and Mayer D.J. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 62 (1995) 259-274
4. Munglani R., and Hunt S.P. Molecular biology of pain. Br J Anaesth 75 (1995) 186-192
5. King T., Ossipov M.H., Vanderah T.W., Porreca F., and Lai J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance?. Neurosignals 14 (2005) 194-205
6. Galer B.S., Lee D., Ma T., Nagle B., and Schlagheck T.G. MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain 115 (2005) 284-295
7. Price D.D., Mao J., Frenk H., and Mayer D.J. The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain 59 (1994) 165-174
8. Hoffmann O., and Wiesenfeld-Hallin Z. Dextromethorphan potentiates morphine antinociception but does not reverse tolerance in rats. Neuroreport 7 3 (1996) 838-840
9. Mao J., Price D.D., Caruso F.S., and Mayer D.J. Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats. Pain 67 (1996) 361-368
10. Advokat C., and Rhein F. Potentiation of morphine-induced antinociception in acute spinal rats by the NMDA antagonist dextrorphan. Brain Res 699 1 (1995) 157-160
11. Manning B.H., Mao J., Frenk H., Price D.D., and Mayer D.J. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain 67 (1996) 79-88
12. Chevlen EM. MS/DM, morphine with dextromethorphan, an NMDA (N-methyl D-aspartate) receptor antagonist: a new analgesic for moderate to severe pain. [Abstract]. Proceedings of the American Society of Clinical Oncology 18, 1999, p. 582a.
13. Mercadante S., Casuccio A., and Genovese G. Ineffectiveness of dextromethorphan in cancer pain. J Pain Symptom Manage 16 5 (1998) 317-322
14. Nelson K.A., Park K.M., Robinovitz E., Tsigos C., and Max M.B. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 48 (1997) 1212-1218
15. Sang C.N., Booher S., Gilron I., Parada S., and Max M.B. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia. Efficacy and dose-response trials. Anesthesiology 96 (2002) 1053-1061
16. Kinnman E., Nygards E.B., and Hansson P. Effects of dextromethorphan in clinical doses on capsaicin-induced ongoing pain and mechanical hypersensitivity. J Pain Symptom Manage 14 4 (1997) 195-201
17. McQuay H.J., Carroll D., Jadad A.R., et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomized controlled crossover trial with integral n-of-1 design. Pain 59 (1994) 127-133
18. Kissin I. Tolerance to opioid analgesia: why do we differ from rats?. Anesth Analg 101 (2005) 1727-1729
19. Jadad A.R. Opioids in the treatment of neuropathic pain: a systematic review of controlled clinical trials. In: Bruera E., and Portenoy R.K. (Eds). Topics in palliative care (1998), Oxford University Press, New York 31-40